Navigation Links
LSUHSC research increases understanding of drug metabolism
Date:3/17/2010

New Orleans, LA Research led by Wayne L. Backes, PhD, Professor of Pharmacology and Associate Dean for Research at LSU Health Sciences Center New Orleans School of Medicine, has found that drug metabolism depends not only upon which enzymes are present in an individual, but also how they interact, and that can be the difference in whether a drug is safely eliminated from the body or is converted into a toxic or carcinogenic byproduct. The paper will be published in the March 19, 2010 issue of the Journal of Biological Chemistry.

Dr. Backes and his LSUHSC research colleagues J. Robert Reed, PhD, Pharmacology Assistant Professor and Marilyn Eyer, Research Associate have been studying an enzyme called Cytochrome P450 which is responsible for the removal of the majority of drugs from the body by chemically breaking them down into inactive substances or metabolites. There are many different P450 enzymes capable of degrading many different drugs. Because there are so many, there is a high degree of variability in people's responses to a drug.

"Although most P450 reactions lead to metabolites that speed the excretion of drugs and pollutants, sometimes P450 enzymes can lead to the activation of a compound to a metabolite that can cause cancer or toxicity where the initial chemical in the drug does not," notes Dr. Backes. "This is a partial explanation of why some people are more resistant to cancer and other diseases and why it is very important to understand the reasons for the variability in drug metabolism."

The results reported in this paper show that P450 enzymes form complexes with each other in biological membranes, and that these complexes affect how the enzymes metabolize substances, making one of the P450s more active and the other less active. The researchers also showed that both of the P450 enzymes they studied (1A2 and 2B4) had to be in the same membrane inside the cell for that to happen.

"Our study shows that the P450s should not be tested alone, but need to be present in mixtures similar to those found in humans in order to better predict how rapidly a candidate drug is metabolized and eliminated or even whether it can produce toxic byproducts in some individuals," said Dr. Backes. "This information is crucial to the development of new drugs because differences in drug metabolism can lead to differences not only in potential toxicity, but also in the effectiveness of a candidate drug."


'/>"/>

Contact: Leslie Capo
lcapo@lsuhsc.edu
504-568-4806
Louisiana State University Health Sciences Center
Source:Eurekalert

Related biology news :

1. LSUHSC researcher finds first inherited prostate cancer genetic mutation in African-American men
2. LSUHSC awarded multi-million dollar grant to reduce pneumonia
3. LSUHSCs England plays key role in developing new ALS treatment guidelines
4. LSUHSC researchers working to prevent diabetic neuropathy
5. Grant supports LSUHSC research on how like cell receptor systems determine very different functions
6. LSUHSC shows for first time infant inhalation of ultrafine air pollution linked to adult lung disease
7. LSUHSCs Bazan awarded ARRA grant to preserve vision
8. LSUHSC research helps link schizophrenia to specific DNA region
9. LSUHSCs Kolls awarded $1.8 million to improve vaccine strategies for P. carinii pneumonia
10. LSUHSC research describes function of key protein in cancer spread
11. LSUHSC public health researcher finds reason for weight gain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and Company ... data evaluating galcanezumab for the prevention of migraine at ... will take place April 22-28, 2017, in ... four abstracts at AAN, including safety and patient outcomes ... associated with a reduction in monthly migraine headache days ...
(Date:4/20/2017)... , ... April 20, 2017 , ... ... sources for advanced technology applications, announced today that Chief Executive Officer (CEO) Debbie ... SEMI is the global industry association connecting the electronics manufacturing supply ...
(Date:4/20/2017)... , April 20, 2017 For ... focuses on novel drug development and clinical research aimed at ... Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite ... ZIOP ). You can access our complimentary research reports ... ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark ... Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, ... trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic ...
Breaking Biology Technology: